News
LUSTGARTEN FUNDED RESEARCH: An adjuvant treatment regimen that included autogene cevumeran, an investigational individualized neoantigen-specific mRNA vaccine, induced durable and functional T-cell responses that were associated with a reduced risk […]
LUSTGARTEN FUNDED RESEARCH: A novel treatment for leukemias and lymphomas that arise from immune system T cells, developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig […]
LUSTGARTEN FUNDED RESEARCH: Researchers at the University of Toronto’s Donnelly Centre for Cellular and Biomolecular Research have found two enzymes that work against the chemotherapy drug gemcitabine, preventing it from effectively treating […]
In 2022, your generosity fueled Lustgarten-funded researchers’ significant progress in pancreatic cancer research. Together, we are advancing research from the laboratory to the clinic faster than ever before, giving renewed […]
The American Cancer Society (ACS) has released its Cancer Facts & Figures 2023, an annual summary of the current scientific information about cancer. The report highlighted progress in the five-year […]
This is a randomized multicentre phase II trial with a large translational component. The trial will evaluate the two standard chemotherapy regimens: modified folfirinox (mFFX) and gemcitabine/nab-paclitaxel (GA), in patients […]
A report compiled by the National Cancer Institute, the Centers for Disease Control and Prevention, the American Cancer Society, and the North American Association of Central Cancer Registries, Annual Report […]
Cancer deaths continue downward trend; modest improvements in survival for pancreatic cancer